CIK 1567892

Keenova Therapeutics plc

EDGAR filings

Customers

2 disclosed

Suppliers

None disclosed

Largest customer

46%

FFF Enterprises, Inc. · FY to 2025-12-31

Named-customer revenue

$658.1M

1 customer · FY to 2025-12-31

Latest period

Dec 31, 2025

10-K filed 2026-04-15

Band height is the estimated dollar value: the disclosed share × the discloser's revenue for that period (latest full year where available) or federal dollars obligated. Each side is scaled on its own; dashed outlines are named without a figure. Click a band to open its source.

Customers 2

Companies Keenova Therapeutics plc discloses as major customers, as a share of Keenova Therapeutics plc revenue. 2 active, 0 lapsed.

Company	% of Keenova Therapeutics plc revenue	Est. revenue	Period	Trend	Status	Source
FFF Enterprises, Inc. Non-SEC FFF Enterprises, Inc.	46%	$658.1M	FY 2025-12-31	+3.8pp	Active	10-K 2026-04-15
FFF Enterprises, Inc. 46.0 % 42.2 % 40.2 % 38.1 % 10-K filed 2026-04-15 Period FY 2024-12-28 to 2025-12-31 (46%), FY 2023-12-30 to 2024-12-27 (42.2%), FY 2022-12-31 to 2023-12-29 (40.2%)Accession 0001628280-26-025238
COR Distributor Cencora, Inc.	Named	—	FY 2025-12-31	—	Active	10-K 2026-04-15
Cencora, Inc. 47.5 % * 10-K filed 2026-04-15 Period FY 2024-12-28 to 2025-12-31Accession 0001628280-26-025238

Alerts are coming

Get an email when Keenova Therapeutics plc's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.